drugset
drugset / Trial / NCT05034133

Durvalumab With Chemotherapy Followed by Sequential Radiotherapy for Limited Stage Small Cell Lung Cancer

NCT05034133 ↗

Phase 2 Unknown 20 enrolled Beijing Haidian Hospital
NaSingle-groupOpen-labelTreatment

Summary

This is a single arm Phase II study, in which 6 cycles of durvalumab with chemotherapy (Etoposide and Cisplatin) and durvalumab followed by Sequential radiotherapy for limited stage small cell lung cancer.

Timeline

Start
2021-09-01
Primary completion
2023-08-31
Completion
2024-08-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Durvalumab Monoclonal antibody 1000 mg Intravenous

Indications

small cell lung carcinoma